Analysts Offer Insights on Healthcare Companies: Atossa Genetics (ATOS), VistaGen Therapeutics (VTGN) and Restoration Robotics Inc (HAIR)


There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Atossa Genetics (NASDAQ:ATOS), VistaGen Therapeutics (NASDAQ:VTGN) and Restoration Robotics Inc (NASDAQ:HAIR) with bullish sentiments.

Atossa Genetics (ATOS)

Maxim Group analyst Jason McCarthy maintained a Buy rating on Atossa Genetics today and set a price target of $10. The company’s shares closed yesterday at $2.26, close to its 52-week low of $2.01.

McCarthy noted:

“Atossa reported 2Q18 with operating expenses of $4.1M, of which $1.5M was non-cash. The company ended the period with $15.2M in cash, runway into 2H19 and through multiple catalysts.”

According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 11.6% and a 42.8% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Atossa Genetics with a $10 average price target.

See today’s analyst top recommended stocks >>

VistaGen Therapeutics (VTGN)

Maxim Group analyst Caroline Palomeque maintained a Buy rating on VistaGen Therapeutics today and set a price target of $6. The company’s shares closed yesterday at $1.28.

Palomeque noted:

“VistaGen announced a collaboration with the a first-step study of AV-101 in healthy volunteer veterans from either Operation Enduring Freedom, Operation Iraqi Freedom, or to evaluate potential anti-suicidal effects. Funding for trial materials and costs will be provided for through VistaGen’s CRADA agreement with the US Affairs (VA).”

According to TipRanks.com, Palomeque has currently no stars on a ranking scale of 0-5 stars, with an average return of -8.8% and a 34.7% success rate. Palomeque covers the Healthcare sector, focusing on stocks such as Soleno Therapeutics Inc, Anavex Life Sciences, and Neurotrope.

VistaGen Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $11.33.

Restoration Robotics Inc (HAIR)

Maxim Group analyst Anthony Vendetti maintained a Buy rating on Restoration Robotics Inc today and set a price target of $6. The company’s shares closed yesterday at $1.56, close to its 52-week low of $1.45.

Vendetti noted:

“Market close, HAIR announced the pricing of its $15M equity offering, downsized from $25M, at $1.50 per share. The offering is expected to close on August 14, 2018. Although we are reducing our price target due to greater-than-expected dilution, we remain optimistic about HAIR’s growth potential, especially given the major improvements featured in its ARTAS iX System.”

According to TipRanks.com, Vendetti is a 4-star analyst with an average return of 9.1% and a 55.7% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Ellex Medical Lasers Limited, Xtant Medical Holdings, and Milestone Scientific.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Restoration Robotics Inc with a $8 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts